MAPK1 and renal cell carcinoma: Although BRAF is not mutated in RCC, VEGFR-2 may be aberrantly expressed as there is dysregulation of its cognate ligand VEGF which can activate VEGFR2 and the Raf/MEK/ERK cascade.